尼拉帕利联合阿比特龙醋酸盐治疗转移性去势抵抗性前列腺癌
MAGNITUDE研究是一项III期随机双盲试验,评估尼拉帕利联合阿比特龙醋酸盐+泼尼松(尼拉帕利+AAP)在HRR阳性或阴性转移性去势抵抗性前列腺癌患者中的疗效。主要终点影像学无进展生存期在BRCA1/2亚组和整体HRR阳性队列中均显著延长。HRR阴性队列因无效而提前终止。
要点
- BRCA1/2亚组中尼拉帕利+AAP组中位rPFS为16.6个月,对照组为10.9个月,HR 0.53。
- 整体HRR阳性队列中尼拉帕利+AAP组中位rPFS为16.5个月,对照组为13.7个月,HR 0.73。
- HRR阴性队列按预设标准判定无效,尼拉帕利+AAP治疗耐受,最常见≥3级不良事件为贫血和高血压。
核心结论
- 在HRR阳性转移性去势抵抗性前列腺癌患者中,与标准治疗AAP相比,尼拉帕利+AAP联合治疗显著延长了影像学无进展生存期。
研究设计与样本
- MAGNITUDE(NCT03748641)是一项III期随机双盲研究,评估尼拉帕利+阿比特龙醋酸盐+泼尼松(尼拉帕利+AAP)治疗有(HRR+,n=423)或无(HRR-,n=247)HRR相关基因突变的患者,突变由组织/血浆检测前瞻性确定。
- 患者按1:1随机接受尼拉帕利+AAP或安慰剂+AAP,主要终点为中央评估的影像学无进展生存期(rPFS),先在BRCA1/2亚组评估,再在整体HRR+队列评估。
- 若rPFS有统计学意义,则分析整体HRR+队列的次要终点;HRR-队列预设了无效性分析。
主要发现
- BRCA1/2亚组中,尼拉帕利+AAP组中位rPFS为16.6个月,安慰剂+AAP组为10.9个月,HR 0.53(95% CI 0.36-0.79),P=0.001。
- 整体HRR+队列中,尼拉帕利+AAP组中位rPFS为16.5个月,安慰剂+AAP组为13.7个月,HR 0.73(95% CI 0.56-0.96),P=0.022。
- 次要终点至症状进展时间和至开始细胞毒性化疗时间在尼拉帕利+AAP组有改善,支持主要发现。
- HRR-队列按预设标准判定无效。
关键数值与推荐
- BRCA1/2亚组中位rPFS:尼拉帕利+AAP组16.6个月 vs 安慰剂+AAP组10.9个月,HR 0.53(95% CI 0.36-0.79),P=0.001。
- 整体HRR+队列中位rPFS:尼拉帕利+AAP组16.5个月 vs 安慰剂+AAP组13.7个月,HR 0.73(95% CI 0.56-0.96),P=0.022。
- HRR-队列按预设标准判定无效。
临床怎么用
- 对于HRR阳性转移性去势抵抗性前列腺癌患者,尼拉帕利+AAP联合治疗较标准治疗AAP显著延长rPFS。
- 尼拉帕利+AAP治疗耐受,最常见≥3级不良事件为贫血和高血压。
- HRR阴性患者中尼拉帕利+AAP按预设标准判定无效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS: MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR-, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the BRCA1/2 subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR- cohort. RESULTS: Median rPFS in the BRCA1/2 subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 v 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; P = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR- cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP. UNLABELLED: [Media: see text].
引用
- Chi KN, Rathkopf D, Smith MR, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023. PMID: 36952634. doi:10.1200/JCO.22.01649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。